MONJUVI
Peaktafasitamab-cxix
BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
MONJUVI (tafasitamab-cxix) is tafasitamab-cxix is an fc-modified monoclonal antibody that binds to cd19 antigen expressed on the surface of pre-b and mature b lymphocytes and on several b-cell malignancies, including diffuse large b-cell lymphoma (dlbcl). First approved in 2020.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONJUVI (tafasitamab-cxix) is an Fc-modified CD19-directed monoclonal antibody approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It binds to CD19 on B-cell malignancies and mediates cell lysis through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). In combination with lenalidomide, tafasitamab-cxix demonstrates enhanced anti-tumor activity.
$0.001BPart D
PeakProduct is in peak lifecycle stage with modest Part D utilization; commercial team focus likely on market penetration and payer access expansion in second-line DLBCL setting.
Mechanism of Action
Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MONJUVI offers career opportunities in an established peak-lifecycle biologic franchise focused on oncology and cell therapy mechanisms. Roles emphasize payer negotiation, physician engagement in hematology/oncology networks, and combination therapy education as differentiation drivers.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.